Intravenous immunoglobulin modulates lymphocyte CD54 and monocyte FcγRII expression in patients with chronic inflammatory neuropathies

• Published in: Journal of neuroimmunology Vol. 135; no. 1; pp. 91 - 95
• Main Authors: Créange, A, Gregson, N.A, Hughes, R.A.C
• Format: Journal Article
• Language: English
• Published: Elsevier B.V 01-02-2003
• Subjects: Inflammatory neuropathy; Integrins; Intravenous immunoglobulin; Intravenous immunoglobulin; Inflammatory neuropathy; Integrins
• ISSN: 0165-5728; 1872-8421
• DOI: 10.1016/S0165-5728(02)00430-7

We studied the expression of different lymphocyte and monocyte cellular determinants involved in leukodiapedesis and antigen presentation in 10 patients with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) and multifocal motor neuropathy (MMN) with persistent conduction blocks before intravenous immunoglobulin (IVIg), immediately after infusion of IVIg and 1 week after infusion. We observed a decrease of T lymphocytes expressing ICAM-1 (CD54) immediately after infusion in 8 out of 10 patients (
p<0.04) with a return to pretreatment values after 1 week. The monocytes showed an increase in CD14
+ cells and CD14
+ FcγRII inhibitory receptor positive cells, no change in the number of CD14
+ FcγRIII activation receptor cells, and an increase in the FcγRII/FcγRIII ratio on monocytes 1 week after IVIg. Thus, the mechanism of action of IVIg in both CIDP and MMN may involve inhibition of T cell transmigration and modulation of antigen presentation capacities through FcγR expression.